Lupus & antiphospholipid syndrome
Type I Interferon status and clinical manifestations in a large cohort of patients with systemic lupus erythematosus
Authors' conclusion
Patients with an elevated IGS have more active and severe disease, accumulating more autoantibodies and requiring increased immunosuppression.
Study context
- Population
- Patients with SLE from the Toronto Lupus Clinic
- Participants
- 506 patients
- Exposure
- Interferons (IFN)-high vs IFN-low SLE patients
- IFN-highn = 291
- IFN-lown = 215reference
- Outcome
- Clinical and serological characteristics by IFN status
Methodological detailssingle-centre (Toronto Lupus Clinic), multivariable analysis
- Single-centre (Toronto Lupus Clinic)
- Multivariable analysis
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
Age at study entry
Disease duration
GC use
Immunosuppressant use
Mycophenolate use
Original publication
Type I Interferon status and clinical manifestations in a large cohort of patients with systemic lupus erythematosus. Joint Bone Spine. Published 26 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →